Get Free Access to Session Slides


The Future of Biomarkers in Advanced Prostate Cancer - Mark Rubin

In this conversation with Charles Ryan, Mark Rubin highlights the key points he addresses in his 2019 Advanced Prostate Cancer Consensus Conference presentation where he speaks about the future of biomarkers in advanced prostate cancer. Biographies: Mark A. Rubin, MD, Professor, Principal Investigator, and Director Department for BioMedical Research (DBMR), University of Bern, Switzerland. Dr. Rub...

Management of Castration-Resistant Prostate Cancer - Cora Sternberg

Cora Sternberg joins Alicia Morgans and shares highlights from the Management of castration-resistant prostate cancer session at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC) and key takeaways from the session when thinking about managing these patients with this disease. She highlights Professor Michael Hofman's presentation on PSMA Targeted Therapies focusing on Lutetium PSMA sc...

Guiding First Line Treatment Decisions for mCRPC After ADT + Docetaxel or AR Pathway Inhibitor - Mary-Ellen Taplin

Mary-Ellen Taplin joins Alicia Morgans to share highlights from her 2019 Advanced Prostate Cancer Consensus Conference (APCCC) presentation on first line treatment of metastatic castration-resistant prostate cancer (mCRPC) after patients have received either docetaxel or abiraterone, enzalutamide, or apalutamide and the lack of data to guide treating physicians in this treatment setting. She highl...

Radiation Therapy Options for Men with Newly Diagnosed cN1 cM0 Prostate Cancer - Mack Roach

Mack Roach presents on radiotherapy options for patients with clinically node-positive prostate cancer at the 2019 Advanced Prostate Cancer Consensus Conference (APCCC). Dr. Roach touches on areas such as the optimal candidate for salvage lymph node dissection (SLND) for nodal recurrence of prostate cancer, the role of adding ADT to radiotherapy, and the NRG/RTOG 9413 study which showed whole pelv...

How Best to Treat cN1 Prostate Cancer - Karim Fizazi

Karim Fizazi summarizes how best to treat node-positive (cN+) prostate cancer patients at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). There are over 20 randomized controlled trials in localized and advanced prostate cancer that have been published according to Dr. Fizazi, yet he notes, none have been published in the setting of node-positive prostate cancer. In this presentatio...

Ethnicity and Prognosis of Prostate Cancer - Christopher Logothetis

Christopher Logothetis presents on the ethnicity and prognosis of prostate cancer during the Regional Care (Demographic and Environmental Factors) Session at the Advanced Prostate Cancer Consensus Conference the (APCCC 2019). Dr. Logothetis discusses the significant difference in the incidence and mortality of prostate cancer worldwide. There are greater differences in the incidence rates than in...

The Definition and Overview of Treatment Options in nmCRPC Presentation - Howard Scher

Howard Scher presents an overview of treatment options for non-metastatic castration-resistant prostate cancer, (nmCRPC), those patients who never had detectable metastases on “conventional/standard” imaging, which includes a radionuclide bone scan and CT abdomen/pelvis +/- and MRI. These patients are generally asymptomatic from cancer itself with some symptoms from prior therapies. Importantly, t...

Local Treatment of the Primary Tumor (Radiotherapy) in the Metastatic Setting - Robert Bristow

In this presentation, Robert Bristow speaks on the concept of local radiotherapy to the primary tumor in the metastatic prostate cancer setting at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019. Dr. Bristow's presentation covers the concept of oligometastatic disease, the rationale for treating the primary tumor, and the future role of metastases-directed therapy including differen...

Testosterone Measurement – Which Test and When? - Martin Gleave

Martin Gleave presents on the topic of testosterone measurement and its various nuances in the context of advanced prostate cancer at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Testosterone measurement is important as androgens are the drivers of activity of the androgen receptor. Dr. Gleave supports the periodic assessment of testosterone levels to ensure castrate levels, wit...

The Risk of Dose De-intensifying Treatment, Bone Health in Prostate Cancer - Fred Saad

Alicia Morgans and Fred Saad have a discussion on bone health in prostate cancer patients, an issue for men with advanced prostate cancer and an important topic to keep at the forefront of care. Even though men are living longer, bone metastases increases mortality and impair a person's independence. Fred and Alicia tackle approaching this in your patients, specifically in the metastatic castratio...
email news signup